PDS Biotechnology Corp 8-K

What Happened PDS Biotechnology Corporation (PDSB) filed an 8-K on April 15, 2026 announcing that clinical and immunological biomarker data from Stage 1 of its Phase 2 trial of PDS01ADC, a tumor‑targeted IL‑12 immunocytokine, were published in the March 10, 2026 issue of Journal of Clinical Oncology (JCO) Oncology Advances. The company issued a press release dated April 15, 2026 (filed as Exhibit 99.1) to report the publication.

Key Details

• Data published: clinical and immunological biomarker results from Stage 1 of the Phase 2 PDS01ADC trial.
• Journal/date: JCO Oncology Advances, March 10, 2026 issue.
• SEC filing date: 8-K filed April 15, 2026; press release included as Exhibit 99.1.
• Investigational agent: PDS01ADC, a tumor‑targeted IL‑12 immunocytokine.

Why It Matters A peer‑reviewed publication of Stage 1 clinical and biomarker data provides independent visibility of PDSB’s clinical progress and the scientific details of its PDS01ADC program. For investors, this confirms the company is publicly reporting trial data in a recognized oncology journal and may support greater transparency around the molecule’s clinical and immunologic profile; the filing itself does not announce new financial results or regulatory decisions.